Chung Byung Min, Raja Srikumar M, Clubb Robert J, Tu Chun, George Manju, Band Vimla, Band Hamid
Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE 68198-5950, USA.
BMC Cell Biol. 2009 Nov 30;10:84. doi: 10.1186/1471-2121-10-84.
Epidermal growth factor receptor (EGFR) controls a wide range of cellular processes, and altered EGFR signaling contributes to human cancer. EGFR kinase domain mutants found in non-small cell lung cancer (NSCLC) are constitutively active, a trait critical for cell transformation through activation of downstream pathways. Endocytic trafficking of EGFR is a major regulatory mechanism as ligand-induced lysosomal degradation results in termination of signaling. While numerous studies have examined mutant EGFR signaling, the endocytic traffic of mutant EGFR within the NSCLC milieu remains less clear.
This study shows that mutant EGFRs in NSCLC cell lines are constitutively endocytosed as shown by their colocalization with the early/recycling endosomal marker transferrin and the late endosomal/lysosomal marker LAMP1. Notably, mutant EGFRs, but not the wild-type EGFR, show a perinuclear accumulation and colocalization with recycling endosomal markers such as Rab11 and EHD1 upon treatment of cells with endocytic recycling inhibitor monensin, suggesting that mutant EGFRs preferentially traffic through the endocytic recycling compartments. Importantly, monensin treatment enhanced the mutant EGFR association and colocalization with Src, indicating that aberrant transit through the endocytic recycling compartment promotes mutant EGFR-Src association.
The findings presented in this study show that mutant EGFRs undergo aberrant traffic into the endocytic recycling compartment which allows mutant EGFRs to engage in a preferential interaction with Src, a critical partner for EGFR-mediated oncogenesis.
表皮生长因子受体(EGFR)控制着广泛的细胞过程,EGFR信号改变与人类癌症相关。在非小细胞肺癌(NSCLC)中发现的EGFR激酶结构域突变体具有组成性活性,这一特性对于通过激活下游途径实现细胞转化至关重要。EGFR的内吞运输是一种主要的调节机制,因为配体诱导的溶酶体降解会导致信号终止。虽然众多研究已对突变型EGFR信号进行了检测,但在NSCLC环境中突变型EGFR的内吞运输情况仍不太清楚。
本研究表明,NSCLC细胞系中的突变型EGFRs会组成性地被内吞,这可通过它们与早期/再循环内体标志物转铁蛋白以及晚期内体/溶酶体标志物LAMP1的共定位来证明。值得注意的是,在用内吞再循环抑制剂莫能菌素处理细胞后,突变型EGFRs而非野生型EGFR会出现核周积累并与再循环内体标志物(如Rab11和EHD1)共定位,这表明突变型EGFRs优先通过内吞再循环区室进行运输。重要的是,莫能菌素处理增强了突变型EGFR与Src的结合及共定位,表明通过内吞再循环区室的异常转运促进了突变型EGFR - Src的结合。
本研究结果表明,突变型EGFRs会异常进入内吞再循环区室,这使得突变型EGFRs能够与Src进行优先相互作用,而Src是EGFR介导的肿瘤发生的关键伙伴。